🛰️ Daily AI Frontier
‹ back to 2026-08-27

A binding-to-release strategy for targeted anticancer drug delivery

Research Targeted Drug Delivery

Ranking

Overall 76
Content 90
Popularity 43

Observed public metrics from 1 member.

Merged summary

TL;DR - This Nature study introduces a binding-to-release drug conjugate strategy that releases anticancer payloads at targeted tumours without requiring cellular internalization. The approach could improve tumour specificity and efficacy while expanding the range of addressable therapeutic targets.

  • Payload release is triggered by target binding rather than uptake into cells.
  • Avoiding the internalization requirement broadens potential targets beyond those suitable for conventional drug conjugates.
  • The strategy is reported to improve tumour-specific delivery and therapeutic efficacy.
  • The provided summary does not include quantitative efficacy or safety results.

Sources (1)

A binding-to-release strategy for targeted anticancer drug delivery

Nature Zihao Wen, Mengxin Xu, Zijun Yan, Ziren Kong, Yupeng Wang, Pei Liu, Junyi Chen, Yanzhao Liu, Xi-Yang Cui, Tianyi Cen, Xinwei Li, Yuedan Zheng, Zichen Gu, Da Xu, Qiang Xu, Yaping Luo, Changlun Wang, Zhibo Liu 2026-08-26 doi:10.1038/s41586-026-10971-0
Public signals OpenAlex citations 0 · Semantic Scholar citations 0 · Semantic Scholar influential citations 0
Providers: Hugging Face · N/A OpenAlex · Citations 0 Publisher · N/A Semantic Scholar · Citations 0 · Influential citations 0 X · N/A Fetched 2026-09-25 14:27:34.491394 UTC

TL;DR - This Nature study introduces a binding-to-release drug conjugate strategy that releases anticancer payloads at targeted tumours without requiring cellular internalization. The approach could improve tumour specificity and efficacy while expanding the range of addressable therapeutic targets.

  • Payload release is triggered by target binding rather than uptake into cells.
  • Avoiding the internalization requirement broadens potential targets beyond those suitable for conventional drug conjugates.
  • The strategy is reported to improve tumour-specific delivery and therapeutic efficacy.
  • The provided summary does not include quantitative efficacy or safety results.
item →